Echinomycin: The first bifunctional intercalating agent in clinical trials
The DOI matches its Crossref record; 16 of the 18 references it cites were found in a registry or an index.
Abstract
Echinomycin is a quinoxaline antibiotic that was originally isolated from Streptomyces echinatus. Based on its antitumor activity against two i.p. implanted murine tumors, the B16 melanoma, and the P388 leukemia, it was brought into clinical trials by the National Cancer Institute. Recent studies on its cytotoxic action have related its antitumor activity with its ability to bifunctionally intercalate with double stranded DNA. Toxicologic studies were carried out in CDF1 mice and beagle dogs using intravenous injections. For the mice studies the dose ranges were 288-692 mcg/kg (864-2076 mcg/m2) by single bolus, and 112-254 mcg/kg/day (336-762 mcg/m2/day) for five consecutive days. In the dog, dose ranges studied were 8.9-89.4 mcg/kg (178-1788 mcg/m2) by single bolus, and 3.4-33.5 mcg/kg/day (68-670 mcg/m2/day) for five consecutive days. The major toxic effects were found in the gastrointestinal, hepatic, and lymphoreticular systems. These were reversible at all but the highest dose, in dogs that had been treated for five consecutive days. Phase I clinical trials using various intravenous schedules were sponsored by the National Cancer Institute. Nausea, vomiting, reversible liver enzyme abnormalities, and allergic reactions were the most common toxicities encountered. Based on results from these studies, the National Cancer Institute has recently begun phase II trials in a broad range of diseases. These trials will further characterize echinomycin's toxic effects and its anti…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, minimal or no antitumor activity was found in phase II clinical trials.”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [47]
In the citing paper
“NSC-13502 was brought into clinical trials by the NCI 20 years ago based on its antitumor activity against two i.p. implanted murine tumors, the B16 melanoma and the P388 leukemia (47).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [47]
In the citing paper
“NSC-13502, at 1.2 to 1.5 mg/m 2 once weekly for 4 weeks or once every 3 to 4 weeks (47-50), has been extensively tested in phase I-II clinical trials.”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [47]
Citations
Cites
The Molecular Basis of Antibiotic Action
Gale, E. F. (1981) · Medical Entomology and Zoology · Cited by 1,217
Base Specificity in the Interaction of Polynucleotides with Antibiotic Drugs
Ward, D. C., Reich, E., & Goldberg, I. H. (1965) · Science · doi:10.1126/science.149.3689.1259 · Cited by 477
The Molecular Structure of a DNA-Triostin A Complex
Wang, A. H.-J., Ughetto, G., Quigley, G. J., Hakoshima, T., van der Marel, G. A., van Boom, J. H., & Rich, A. (1984) · Science · doi:10.1126/science.6474168 · Cited by 292
Echinomycin: a bifunctional intercalating antibiotic
Waring, M. J., & Wakelin, L. P. G. (1974) · Nature · doi:10.1038/252653a0 · Cited by 282
Echinomycin Binding Sites on DNA
Van Dyke, M. M., & Dervan, P. B. (1984) · Science · doi:10.1126/science.6089341 · Cited by 218 · cited 1×
“reasons for this preference were demonstrated in recent studies by van Dyke and Dervan utilizing a DNA footprinting method using methidiumpropylEDTA-Fe(II) as the DNA cleaving agent (15).”
MethodThe binding of echinomycin to deoxyribonucleic acid
Wakelin, L. P. G., & Waring, M. J. (1976) · Biochemical Journal · doi:10.1042/bj1570721 · Cited by 161
Stoffwechselprodukte von Actinomyceten. 7. Mitteilung. Echinomycin
Corbaz, R., Ettlinger, L., Gäumann, E., Schierlein, W. K., Kradolfer, F., Neipp, L., Prelog, V., Reusser, P., & Zähner, H. (1957) · Helvetica Chimica Acta · doi:10.1002/hlca.19570400124 · Cited by 96
Huang, C.-H., Mirabelli, C. K., Mong, S., & Crooke, S. T. (1983) · PubMed · Cited by 41
Studies on quinoxaline antibiotics. II. Isolation and properties of quinomycins A, B and C.
Yoshida, T., KATAGIRI, K., & YOKOZAWA, S. (1961) · PubMed · Cited by 34
Waring, M. J., & MAKOFF, A. J. (1974) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13977-1 · Cited by 34
Research works printed but not linked: 2
- Bhatia MC, Thyagarojan TR, Srivastova OP, Anand N, Vora VC: Quinoxaline antibiotics from a Streptomyces species. Indian J Chem 1:277–278, 1963
- Katagiri K, Sugiura K: Antitumor action of the quinoxaline antibiotics. Antimicrob Agents Chemother, (1961): pp. 162–168, 1961
Cited by
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
“implanted murine tumors, the B16 melanoma and the P388 leukemia (47).”
BackgroundModulating Hypoxia-Inducible Transcription by Disrupting the HIF-1–DNA Interface
Nickols, N. G., Jacobs, C. S., Farkas, M. E., & Dervan, P. B. (2007) · ACS Chemical Biology · doi:10.1021/cb700110z · Cited by 126
A Forward Chemical Screen Identifies Antibiotic Adjuvants in Escherichia coli
Taylor, P. L., Rossi, L., Pascale, G. D., & Wright, G. D. (2012) · ACS Chemical Biology · doi:10.1021/cb300269g · Cited by 81
Alshaer, W., Zraikat, M. S., Amer, A., Nsairat, H., Lafi, Z., Alqudah, D. A., Qadi, E. A., Alsheleh, T., Odeh, F., Alkaraki, A., et al. (2019) · RSC Advances · doi:10.1039/c9ra05636j · Cited by 73
Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells
Ponnurangam, S., Dandawate, P. R., Dhar, A., Tawfik, O. W., Parab, R., Mishra, P. D., Ranadive, P., Sharma, R. K., Mahajan, G., Umar, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6560 · Cited by 64
“Several studies have shown that it has antitumor activity with the ability to bifunctionally intercalate with double stranded DNA [5].”
BackgroundInfluentialCorbett, T. H., LoRusso, P. M., Demchik, L. L., Simpson, C., Pugh, S., White, K., Kushner, J., Polin, L., Meyer, J., Czarnecki, J., et al. (1998) · Investigational New Drugs · doi:10.1023/a:1006174622061 · Cited by 64
Tsuzuki, T., Okada, H., Cho, H., Tsuji, S., Nishigaki, A., Yasuda, K., & Kanzaki, H. (2012) · Human Reproduction · doi:10.1093/humrep/der405 · Cited by 63
“exhibits potent anti-proliferative effects on several tumor-derived cell lines (Foster et al., 1985; Gradishar et al., 1995).”
BackgroundHypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015)
Ban, H. S., Uto, Y., Won, M., & Nakamura, H. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1146252 · Cited by 44
Magagnin, M. G., Koritzinsky, M., & Wouters, B. G. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.07.002 · Cited by 44
Natural Products–Pyrazine Hybrids: A Review of Developments in Medicinal Chemistry
Chen, G., Guo, H.-Y., Quan, Z., Shen, Q., Li, X., & Luan, T. (2023) · Molecules · doi:10.3390/molecules28217440 · Cited by 52
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)
Ban, H. S., Uto, Y., & Nakamura, H. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1874345 · Cited by 44
Echinomycin inhibits adipogenesis in 3T3-L1 cells in a HIF-independent manner
Yamaguchi, J., Tanaka, T., Saito, H., Nomura, S., Aburatani, H., Waki, H., Kadowaki, T., & Nangaku, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-06761-4 · Cited by 36
Lu, Q., Ye, J.-J., Huang, Y., Liu, D., Liu, L., Dong, K., Razumova, E. A., Osterman, I. А., Владимирович, С. П., Dontsova, O. А., et al. (2019) · Antibiotics · doi:10.3390/antibiotics8040236 · Cited by 37
“The result was in accordance with the screening result of crude extract of B475 on the double fluorescent protein reporter system, since echinomycin is widely known as the first DNA bisintercalator [50,51] and definitely can activate an SOS-response to induce expression of RFP in pDualrep2.”
BackgroundResultCharacterization of the bisintercalative DNA binding mode of a bifunctional platinum-acridine agent
Choudhury, J. R. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki869 · Cited by 36
“Since the discovery of echinomycin, a bioactive natural product consisting of two quinoxaline chromophores linked by a bicyclic peptide, bifunctional intercalating agents, both natural and synthetic, have demonstrated promising antimicrobial and antitumor properties (4).”
BackgroundSayers, E. W., & Waring, M. J. (1993) · Biochemistry · doi:10.1021/bi00086a014 · Cited by 36
Tang, Z., Zhang, Z., Lin, Q., Xu, R., Chen, J., Wang, Y., Zhang, Y., Tang, Y., Shi, C., Liu, Y., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.619924 · Cited by 42
“To examine the possible role of HIF-1α signaling during the formation of corpus luteum from the pregnant rats, echinomycin (SigmaAldrich, 75 μg/kg), a potent inhibitor of HIF-1α (Foster et al., 1985), was intraperitoneally injected before mating or execution.”
MethodIn vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus
Park, Y.-S., Shin, W. S., & Kim, S. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm421 · Cited by 35
“In light of excellent antitumour activity and tolerable toxicity in preclinical and Phase 1 trials, echinomycin has been used in a Phase II clinical trial for the treatment of solid types of cancer such as colon cancer and ovarian cancer.(25,26) Therefore, we investigated in vivo applicability.”
BackgroundConversion of a Disulfide Bond into a Thioacetal Group during Echinomycin Biosynthesis
Hotta, K., Keegan, R. M., Ranganathan, S., Fang, M., Bibby, J., Winn, M., Sato, M., Lian, M., Watanabe, K., Rigden, D. J., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201307404 · Cited by 34
Soto‐Sánchez, J., & Ospina‐Villa, J. D. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13921 · Cited by 28
“Quinomycin A is a DNA intercalator (Foster et al., 1985).”
Solution-phase synthesis and biological evaluation of triostin A and its analogues
Hattori, K., Koike, K., Okuda, K., Hirayama, T., Ebihara, M., Takenaka, M., & Nagasawa, H. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob02505b · Cited by 23
Schilsky, R. L., Faraggi, D., Korzun, A., Vogelzang, N., Ellerton, J., Wood, W., & Henderson, I. C. (1991) · Investigational New Drugs · doi:10.1007/bf00176982 · Cited by 21
Ratnayake, A. S., Chang, L.-P., Tumey, L. N., Loganzo, F., Chemler, J. A., Wagenaar, M., Musto, S., Li, F., Janso, J. E., Ballard, T. E., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00843 · Cited by 21
Inhibition of Topoisomerase II by a Novel Antitumor Cyclic Depsipeptide, BE‐22179
Yoshinari, T., Okada, H., Yamada, A., Uemura, D., Oka, H., Suda, H., & Okura, A. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02394.x · Cited by 20
Molecular and Cellular Response of the Myocardium (H9C2 Cells) Towards Hypoxia and HIF-1α Inhibition
Osuru, H. P., Lavallee, M., & Thiele, R. H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.711421 · Cited by 20
“When present, 200 μM (19–21) of Cobalt (II) chloride [(CoCl2), # C8661, Sigma, United States] a Hypoxiainducible transcription factor 1 α (HIF-1 α) inducer, 1 mM of Dimethyloxalylglycine [(DMOG); Sigma, United States, # 400091] a HIF-Hydroxylase Inhibitor, 100 μM (22) of L-Ascorbic acid 2-phosphate sesquimagnesium sal…”
BackgroundPhase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885
Chang, A. Y., Tu, Z. N., Bryan, G. T., Kirkwood, J. M., Oken, M. M., & Trump, D. L. (1994) · Investigational New Drugs · doi:10.1007/bf00874447 · Cited by 16
“It is a cyclic peptide which is isolated from streptomyces echinatus and consists of two planar quinoxaline molecules connected by an octapeptide bridge [ 5 , 6]. It has been shown to inhibit the DNA and RNA syntheses and is active in the preclinical screening.”
BackgroundHegade, P. G., Mane, M. M., Patil, J. D., & Pore, D. M. (2014) · Synthetic Communications · doi:10.1080/00397911.2014.943345 · Cited by 16
Kinder, T. B., Dranchak, P. K., & Inglese, J. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00343 · Cited by 17
Kuhn, J. G., Von Hoff, D. D., Hersh, M., Melink, T., Clark, G. M., Weiss, G. R., & Coltman, C. A. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90123-5 · Cited by 14
Chen, C., Chen, X., Ren, B., Guo, H., Abdel-Mageed, W. M., Liu, X., Song, F., & Zhang, L. (2021) · Journal of Industrial Microbiology & Biotechnology · doi:10.1093/jimb/kuab079 · Cited by 13
“It can bind to DNA by inserting two planar chromophores between the base pair of duplex DNA and place its cyclic depsipeptide backbone in the minor groove (Foster et al., 1985; Waring and Wakelin, 1974).”
BackgroundPark, Y. S., Shin, W., Kim, C.-S., Ahn, C. M., Qi, X.-F., & Kim, S. (2018) · Molecular & Cellular Toxicology · doi:10.1007/s13273-018-0002-8 · Cited by 17
Quinomycin A reduces cyst progression in polycystic kidney disease
Radadiya, P. S., Thornton, M. M., Daniel, E. A., Idowu, J. Y., Wang, W., Magenheimer, B. S., Subramaniam, D., Tran, P. V., Calvet, J. P., Wallace, D. P., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002490r · Cited by 12
Two novel quinomycins discovered by UPLC-MS from Stretomyces sp. HCCB11876
Yang, Z., Shao, L., Wang, M., Rao, M., Ge, M., & Xu, Y. (2018) · The Journal of Antibiotics · doi:10.1038/s41429-018-0132-1 · Cited by 12
Molecular signaling cascade in DNA bisintercalator, echinomycin-induced apoptosis of HT-29 cells
Park, J. Y., Ryang, Y. S., Shim, K. Y., Lee, J. I., Kim, H. S., Kim, Y. H., & Kim, S.-K. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.003 · Cited by 12
“Echinomycin is a cyclic peptide, isolated from Streptomyces echinatus (Wadler et al., 1994; Foster et al., 1985).”
BackgroundThe chemistry of DNA modification by antitumor antibiotics
Fisher, J. F., & Aristoff, P. A. (1988) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-9154-7_12 · Cited by 12
Garcia, M. R., Andrade, P. B., Lefranc, F., & Gomes, N. G. M. (2024) · Marine Drugs · doi:10.3390/md22040143 · Cited by 12
“Echinomycin ( 7 ) was the first bifunctional intercalating agent proceeding to clinical development, but it was discontinued due to its poor effectiveness in patients with solid tumors [78,79].”
BackgroundEchinomycin: A Journey of Challenges
Lafi, Z., Alshaer, W., Hatmal, M. M., Zihlif, M., Asha, N., Abdelnabi, H., & Awidi, A. (2023) · Jordan Journal of Pharmaceutical Sciences · doi:10.35516/jjps.v16i3.918 · Cited by 11
“B16 melanoma, and the P388 leukemia Preclinical Murine/ dogs Conventional formulation/ CrEL-based Toxicity study /LD50 (50)”
Shchekotikhin, A. E., Makarov, I. G., Buyanov, V. N., & PREOBRAZHENSKAYA, M. N. (2005) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-005-0248-7 · Cited by 10
The UvrA ‐like protein Ecm16 requires ATPase activity to render resistance against echinomycin
Erlandson, A., Gade, P., Menikpurage, I. P., Kim, C., & Mera, P. E. (2022) · Molecular Microbiology · doi:10.1111/mmi.14918 · Cited by 9
de Almeida, L. L. C., Fernandes, S. P., de Oliveira, G. D., Silva, M. D. S., de Souza, T. A., Rodrigues-Junior, V. S., & Cibulski, S. P. (2025) · Natural Products and Bioprospecting · doi:10.1007/s13659-025-00533-8 · Cited by 9
“The study of Foster et al. [118] investigated the toxicity of echinomycin in mice and Beagle dogs through intravenous injections administered over five consecutive days, and the primary toxic effects were observed in the gastrointestinal, hepatic, and lymphoreticular systems.”
Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix
Muss, H. B., Blessing, J. A., Eddy, G. L., & McGehee, R. (1992) · Investigational New Drugs · doi:10.1007/bf01275474 · Cited by 8
Newman, R. A., Fuentes, A., Minor, T. Y., McManus, K. T., & Garteiz, D. A. (1994) · Journal of Liquid Chromatography · doi:10.1080/10826079408013360 · Cited by 7
Design and Production of Geranylated Cyclic Peptides by the RiPP Enzymes SyncM and PirF
Xu, Y., Ruijne, F., Diez, M. G., Stada, J. J., & Kuipers, O. P. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00260 · Cited by 8
Xu, L., Ishikawa, H., Zhou, Y., Kobayashi, T., & Shozu, M. (2022) · F&S Science · doi:10.1016/j.xfss.2022.01.005 · Cited by 8
Cytostatics and immunosuppressive drugs
Wierzba, K., Yamada, Y., & Hanano, M. (1988) · Side effects of drugs annual · doi:10.1016/s0378-6080(88)80112-0 · Cited by 6
Petersen, M. E., Brant, M. G., Lasalle, M., Fung, V., Rojas, A. H., Wong, J., Das, S., Barnscher, S. D., Rich, J. R., & Winters, G. C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00760 · Cited by 5
Zamudio-Vázquez, R., Alberício, F., Tulla‐Puche, J., & Fox, K. R. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400323x · Cited by 5
Evaluation of hypoxia inducible factor targeting pharmacological drugs as antileishmanial agents
Campioni, M. D. P., Pereira, J. B., Costa, S. D. S., Salazar-Terreros, M. J., Degrossoli, A., & Giorgio, S. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2016.05.018 · Cited by 5
Herbert, J., Lalé, A., Pereillo, J., Derocq, J., & Casellas, P. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650274 · Cited by 5
Conversion of a Disulfide Bond into a Thioacetal Group during Echinomycin Biosynthesis
Hotta, K., Keegan, R. M., Ranganathan, S., Fang, M., Bibby, J., Winn, M., Sato, M., Lian, M., Watanabe, K., Rigden, D. J., et al. (2013) · Angewandte Chemie · doi:10.1002/ange.201307404 · Cited by 4
Cheng, J., Jin, Y., Yang, S. H., & Suh, J. (2013) · Journal of the Korean Society for Applied Biological Chemistry · doi:10.1007/s13765-012-2227-x · Cited by 4
Xu, Y., & Kuipers, O. P. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00132 · Cited by 5
Synthetic Biology and Therapies for Infectious Diseases
Ando, H., Citorik, R. J., Cleto, S., Lemire, S., Mimee, M., & Lu, T. K. (2014) · Wiley eBooks · doi:10.1002/9783527676132.ch7 · Cited by 4
Quinomycins with an unusual N-methyl-3-methylsulfinyl-alanine residue from a Streptomyces sp
Wang, A., Li, S., Wei, Y., Wang, G., Shi, W., Shang, Y., Yu, L., Chen, S., Li, Y., & Gan, M. (2024) · The Journal of Antibiotics · doi:10.1038/s41429-024-00736-0 · Cited by 2
Scaffolds in cytotoxic drugs and novel antitumor molecules interacting with nucleic acids
Ou, T., Sun, J., Wang, X., & Zou, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00014-0 · Cited by 1
Cellular adaptation to hypoxia and reoxygenation through gene specific mRNA translation
Magagnin, M. G. (2008) · Research Publications (Maastricht University) · doi:10.26481/dis.20080911mm
Class II UvrA protein Ecm16 requires ATPase activity to render resistance against echinomycinPreprint
Erlandson, A., Gade, P., Kim, C., & Mera, P. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.02.478902
Cytostatics and immunosuppressive drugs
Wierzba, K., & Hanano, M. (1987) · Side effects of drugs annual · doi:10.1016/s0378-6080(87)80052-1
Kong, D., Park, E., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A. P., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2023) · doi:10.1158/0008-5472.22365320
Development and Exploitation of RiPPs technology for Peptide Engineering
Xu, Y. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1161821388
Ruddarraju, R. R., Komatani, Y., Tokodai, Y., & Ichikawa, S. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c01110
Chang, A. Y., Kim, K., Boucher, H., Bonomi, P., Stewart, J. A., Karp, D. D., & Blum, R. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980115)82:2<301::aid-cncr8>3.0.co;2-t
Metadata
- Authors
- Foster, B. J., Clagett-Carr, K., Shoemaker, D. D., Suffness, M., Plowman, J., Trissel, L. A., Grieshaber, C. K., & Leyland-Jones, B.
- Affiliations
- National Cancer Institute (US)
- ORCID
- Leyland-Jones, Brian
- Venue
- Investigational New Drugs
- Published
- 1985-12
- Volume
- 3
- Issue
- 4
- Pages
- 403-410
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W2013828999
- Cited by
- 61
- References
- 18
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 1
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Investigational New Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Biological Evaluation
- Keywords
- echinomycin, quinoxaline antibiotics, anticancer activity, B16 melanoma, P388 leukemia, dose-limiting toxicity, gastrointestinal toxicity, hepatotoxicity, intravenous administration, anticancer agents
- MeSH terms
- Animals, Clinical Trials as Topic, Cross-Linking Reagents, DNA, Dogs, Drug Evaluation, Echinomycin, Humans, Lethal Dose 50, Neoplasms, Experimental, Quinoxalines, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.